Radiation therapy is among the most effective and widely used modalities of cancer therapy in current clinical practice. With the advent of new high throughput genomic technologies and the continuous inflow of transcriptomic data, there has been a paradigm shift in the landscape of radiation oncology. In this era of personalized radiation medicine, genomic datasets hold great promise to investigate novel biomarkers predictive of radiation response. These biomarkers may be used to investigate radiation-induced biological events, and to predict clinical outcomes. In this regard, the number of available gene expression based signatures built under oxic and hypoxic conditions is getting larger. This poses two main questions in the field, namely, i) how reliable are these signatures when applied across a compendium of datasets in different model systems; and ii) is there redundancy of gene signatures. To address these fundamental radiobiologic questions, we curated a database of gene expression signatures predictive of radiation response under oxic and hypoxic conditions. RadiationGeneSigDB has a collection of 11 oxic and 24 hypoxic signatures with the standardized gene list as a gene symbol, Entrez gene id along with its function. We present the utility of this database through two case studies: i) comparing breast cancer oxic signatures in cell line data vs. patient data; and ii) comparing the similarity of head and neck cancer hypoxia signatures in clinical tumor data. This valuable, curated repertoire of published gene expression signatures provides a motivating example for how to search for similarities in radiation response for tumors arising from different tissues across model systems under oxic and hypoxic conditions.
INTRODUCTION
The aim of ionizing radiation is to eliminate, with as much certainty as possible, all tumor cells in the primary tumor along with the regional lymph nodes, while at the same time limiting damage to the surrounding non-cancerous tissues. Over the last few decades, improvements to radiation therapy delivery have substantially increased the survival rate of cancer patients (Bernier et al. , 2004) . Many of these advances have been due to technological improvements in radiation delivery and dose conformity, which include particle therapies coupled with advanced image guidance techniques (Baumann et al. , 2016; Verellen et al. , 2007) . These advanced techniques are more precise in targeting the primary tumor volume with relatively lower radiation doses to surrounding healthy tissues, resulting in improved patient survival (Tree et al. , 2013) . Moreover,, the decision-making underlying the stratification of patients into different chemo-radiotherapeutic protocols to date has been based on clinical variables such as tumor stage, histology, age of the patient, gender, etc. derived from interrogation of large population cohorts. However, it is well-supported from several studies that intra-tumor heterogeneity and inter-patient variability are key features that can dictate the tumor response to a certain kind of treatment regimen, be it radiation therapy or chemotherapy, and importantly, this may affect the results and interpretation of these cohort-based studies (Bentzen and Overgaard, 1994; Kozin et al. , 2008; Krause et al. , 2009 ) .
The two pillars driving the field of personalized radiation oncology are: i) treatment delivery and dose conformity arising from technological improvements, which include particle therapies and advanced image guidance techniques; ii) novel biomarker-guided tools, integrating concomitant chemotherapy (Baumann et al. , 2016) . To tailor radiation therapy, it is crucial to build predictive assays that are more confidently able to stratify patients, and concomitantly have associated impactful radiotherapeutic regimens (Peters, 1990) . This could augment the existing radiobiological treatment strategies to more biologically-driven personalized radiation treatment to individual patients. The evolution of new high throughput technologies and the continuous inflow of transcriptomic data have created new avenues to understand complex biological events induced by ionizing radiation, through data driven analysis, at a level beyond the gross clinical variables of an individual, and instead, at the individual tumor level. The ever-expanding arsenal of transcriptomic data holds great promise to investigate novel biomarkers that are predictive of radiation response. In the literature, several studies have attempted to associate radiosensitivity with molecular/genomic features (Scott et al. , 2017) , and this number is getting larger. But, there have been no systematic efforts to build a database of radiation response gene expression signatures validated or designed for clinical use.
In the literature, many groups conducted comprehensive genome-wide assessments of gene expression profiling and built gene expression based signatures for radiation response under oxic and hypoxic conditions. Broadly, two methods have been used to identify these gene signatures, namely, data-driven (bottom-up) and hypothesis-based (top-down) approaches. The performances of these transcriptomic signatures have been evaluated on various datasets with limited to no independent validation. Moreover, there is only minimal overlap between the genes of these different signatures. This may be attributed to the different transcriptomic platforms, such as microarray or RNA-sequencing, training sets, and statistical tools used to build these signatures. Moreover, in order to develop biomarkers reproducible and appropriate for clinical translation, a database should be built to house these predictive models.
At present, there is no radiation response signature database that could potentially address these fundamental questions. A wealth of molecular data (Curtis et al. , 2012; Cancer Genome Atlas Research Network et al. , 2013) and gene expression based signatures ( Subramanian et al. , 2005 ) are publicly available through diverse online resources. In this study, we manually curated a number of radiation response gene signatures from the literature, known as the RadiationGeneSigDB , and implemented this as an R package. This database will facilitate users, i) to compare radiation response signatures across pan-cancer datasets; ii) to investigate the prognostic value of these signatures on a compendium of clinical datasets using meta-analysis; and, iii)
to investigate the tissue specificity of radiation response using these signatures across different transcriptomic platforms. Ultimately, the goal of this work is to improve the development, and spur a greater understanding of how transcriptomic signatures can be used to augment precision radiation oncology, for improved patient outcomes, and more effectively designed clinical trials.
METHODS 2.1 Curation of RadiationGeneSigDB
In most online resources, gene signatures are often included in tables or figures embedded in publications. These signatures often use non-standard gene identifiers, making comparison to other gene signatures, or even to the original data a significant challenge. To be of maximal value, these gene signatures should be available through an easily accessible database resource that provides gene sets in a more standard format. Radiation response gene expression based signatures are identified in Pubmed. In our first release, we collected 11, 24 oxic and hypoxic signatures respectively, and these are described in Supplementary Tables 1 and 2 . We manually annotated them with gene symbol, Entrez Gene ID, and gene function.
Datasets
Cancer cell lines were profiled at the genomic level and the processed data are available for download from a public database, The Cancer Cell Line Encyclopedia (CCLE) (Barretina et al. , 2012) . For this study, we used all breast cancer lines (26 in total) from the CCLE dataset. The METABRIC dataset was used for patient data (Curtis et al. , 2012) and selected only those patients treated with radiation therapy. Out of 1992 patients, 232 patients were reportedly treated with radiation. We retrieved head and neck squamous cell carcinoma (HNSCC) primary tumor transcriptomic data from the Tumor Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Research Network et al. , 2013) , and selected only the patients treated with radiation therapy (99 in total).
Molecular subtyping and signature score
We used the SCMOD2 model (Haibe-Kains et al. , 2012) to assign each tumor sample into the four established molecular subtypes of breast cancer: Basal-like (TNBC), Her2-enriched, Luminal A (ER-high) and Luminal B (ER-low). We used the SCMOD2 implementation available in the genefu package (Gendoo et al. , 2016) . We computed a signed average (the sign being determined by the sign of the gene coefficient or direction) using the sig.score function in genefu . We computed the correlation between the the published gene signatures using the Spearman correlation coefficient.
CASE STUDIES
We present here two case studies utilizing the radiation response gene signature database, highlighting its utility, and the associated R code is provided in the Github.
Comparison of oxic breast gene signatures in cell lines and patients
The objective of this case study is to conduct an unbiased comparison of two different prognostic breast cancer signatures (namely, Piening et al. ) , Speers et al. ) predictive of radiation response under oxic conditions. We compared the signature scores in cell line data as well as in patients, and assessed the similarities and differences in their behavior across these datasets. Importantly, the overlap of genes between these two signatures is minimal, attributable to the different platforms, training sets, and statistical methods used in their generation. We computed signature scores across the 26 breast cancer cell lines from the the CCLE RNA-seq database, as well as for all patient samples from the METABRIC dataset. Before proceeding further with this analysis, we first assayed the quality of gene signature application on each of these datasets using sigQC, as developed in Dhawan et al (Dhawan et al. , 2017) . Interestingly, this precursor analysis, with summary radar plots in Supplementary Figure  1 , showed that there are significant variations in quality between the signatures on different datasets. That is, the signatures appeared to have strongest quality when applied on CCLE data or TNBC data, but not the ER-low subtype. Next, the signature scores for both the Piening and Speers signatures were then compared directly with the Spearman correlation coefficient ( Figure  1 ). We observed a moderate Spearman correlation (~0.69) between the signature scores in the ρ cell line data. However, we observed significant differences when comparing signature scores in patient data. We observed that for clinical data, when stratified by molecular subtype, the Spearman correlation has moderate value for triple negative breast cancer (TNBC), HER2-positive and ER-low cancers. For the ER-high subtype, the Spearman correlation between the signatures is weak (~0.25). The moderate correlation between the two breast cancer ρ signatures can be attributed to: i) different statistical tools implemented on different platforms , with a small overlap in genes; ii) different experimental assays and protocols used to generate dose-response data; iii) inconsistent experimental methodologies to generate data across labs; iv) signature development being underpowered due to lack of sample size along with enough replicates . This could also have implications with regard to the evaluation of radiation response in an in-vitro setting and translating it to the clinical practice. Hence, there is a dire need to build robust radiation signatures that are independent of platforms and technology. 
Comparison of HNSCC hypoxia gene signatures in patients
In this case study, we aimed to compare three HNSCC hypoxia gene expression signatures in the TCGA cohort. The first hypoxia signature is identified by , which was validated in a HNSCC cohort. The second hypoxia signature is developed by on laryngeal tumors, which was validated in HNSCC cohort. Lastly, the third signature was built by , which was derived to determine a pan-cancer signature for radiation response in hypoxia. Firstly, comparing the composition of each of these signatures, we noted that there is just a single common gene between the three signatures. Next, we performed a quality analysis, to ensure legitimacy when applying these signatures on the TCGA dataset with sigQC and noted that all three signatures show good quality on this dataset and are consistent between each other, as shown in the summary radar plots in Supplementary Figure 2 . We found that the Toustrup and Lendahl, and the Toustrup and Eustace hypoxia signatures were strongly correlated (~0.8), whereas the ρ Lendahl and Eustace signatures were weakly correlated (~0.46) (Figure 2-Left panel) , which is ρ consistent with (Tawk et al. , 2016) . Having identified differences in their genetic composition, but relative similarity in the behavior, we next asked whether similar biological processes could be defining these signatures. To achieve this, we performed pathway analysis using the GO terms from the MSigDB (Subramanian et al. , 2005) . For an FDR < 10%, 13, 37, and 51 transcriptional pathways were found to be enriched using Toustrup, Eustace, Lendahl signatures respectively. We found only 3 pathways that were commonly enriched between all the 3 signatures (Figure 2 Right panel), namely, GO:Oxidation_Reduction_Process", "GO:Glucose_Metabolic_Process," GO:Monosaccharide _Metabolic_Process. We found the pathways, "GO: Response_To_Oxygen_levels" and "GO:CellularResponse_Oxygen_Levels" to be enriched related to the oxygen levels using Toustrup and Lendahl signatures, but not enriched using the Eustace signature, as summarized by the Venn diagram in Figure 2 (right). 
CONCLUSION
In this era of personalized medicine, an area of current excitement in the field of radiation oncology is the study of changes in the transcriptome induced by radiation therapy, termed radiogenomics. With the evolution of transcriptomic sequencing technologies, radiogenomics has emerged as a new field to help decode changes in the genetic events induced by radiation therapy, and also identify the biomarkers that are predictive of radiation response. Due to the continuous growth of genome-wide association studies and transcriptomic studies across multiple cancers, the number of biomarkers predictive of radiation response is ever-increasing. The lack of genomic indicators of radiation response has impeded the administration of radiation therapy to individual patients. Moreover, if a predictive biomarker were to be integrated into the clinical practice, it would require a reproducible assay that is agnostic to platforms and technologies. This study is an effort to build a database of radiation response gene signatures under oxic and hypoxic conditions. This repertoire of gene expression based signatures are publicly available as an open source package in R . This will facilitate comparison of radiation response signatures across cancer types, and also enable us to investigate the prognostic value of these signatures using meta-analysis approaches. We hope and envision that this package will help users to compare their own signature to those in the RadiationGeneSigDB database, and help build better biomarkers by using multiple datasets in the discovery, or pre-clinical phase. Furthermore, RadiationGeneSigDB coupled with RadioGx, a novel computational platform of radiogenomics datasets (Manem et al. , 2018) , will enable us to build reliable and clinically-verifiable genomic predictors of radiation response.
